These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 34757217)
1. Design and synthesis of an oral prodrug alalevonadifloxacin for the treatment of MRSA infection. Bhawsar S; Kale R; Deshpande P; Yeole R; Bhagwat S; Patel M Bioorg Med Chem Lett; 2021 Dec; 54():128432. PubMed ID: 34757217 [TBL] [Abstract][Full Text] [Related]
2. Levonadifloxacin, a Novel Broad-Spectrum Anti-MRSA Benzoquinolizine Quinolone Agent: Review of Current Evidence. Bhagwat SS; Nandanwar M; Kansagara A; Patel A; Takalkar S; Chavan R; Periasamy H; Yeole R; Deshpande PK; Bhavsar S; Bhatia A; Ahdal J; Jain R; Patel M Drug Des Devel Ther; 2019; 13():4351-4365. PubMed ID: 31920285 [TBL] [Abstract][Full Text] [Related]
4. Levonadifloxacin, a recently approved benzoquinolizine fluoroquinolone, exhibits potent in vitro activity against contemporary Staphylococcus aureus isolates and Bengal Bay clone isolates collected from a large Indian tertiary care hospital. Bakthavatchalam YD; Shankar A; Muniyasamy R; Peter JV; Marcus Z; Triplicane Dwarakanathan H; Gunasekaran K; Iyadurai R; Veeraraghavan B J Antimicrob Chemother; 2020 Aug; 75(8):2156-2159. PubMed ID: 32361727 [TBL] [Abstract][Full Text] [Related]
5. In vitro bactericidal activity of levonadifloxacin (WCK 771) against methicillin- and quinolone-resistant Staphylococcus aureus biofilms. Tellis M; Joseph J; Khande H; Bhagwat S; Patel M J Med Microbiol; 2019 Aug; 68(8):1129-1136. PubMed ID: 31241446 [TBL] [Abstract][Full Text] [Related]
6. Treatment challenges in the management of difficult-to-treat gram-positive infections: A consensus view apropos therapeutic role of novel anti-MRSA antibiotics, levonadifloxacin (IV) and alalevonadifloxacin (oral). Saseedharan S; Dubey D; Singh RK; Zirpe K; Choudhuri AH; Mukherjee DN; Gupta N; Sahasrabudhe S; Soni S; Kulkarni S; Walse P; Vora AC; Thomas J; Tayade A; Bhadarke G; Kishore K; Paliwal Y; Patil P; Reddy PK; Nagvekar V; Veeraraghavan B Indian J Med Microbiol; 2024; 47():100528. PubMed ID: 38228227 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of a Novel Broad-Spectrum Anti-MRSA Agent Levonadifloxacin Compared with Linezolid for Acute Bacterial Skin and Skin Structure Infections: A Phase 3, Openlabel, Randomized Study. Bhatia A; Mastim M; Shah M; Gutte R; Joshi P; Kumbhar D; Periasamy H; Palwe SR; Chavan R; Bhagwat S; Patel M; Llorens L; Friedland HD J Assoc Physicians India; 2020 Aug; 68(8):30-36. PubMed ID: 32738837 [TBL] [Abstract][Full Text] [Related]
8. Preclinical safety evaluation of levonadifloxacin, a novel anti-methicillin-resistant Staphyloccocus aureus benzoquinolizine fluoroquinolone by intravenous and oral administration. Nandanwar M; Kansagara A; Gupta S; Patel A; Patel MA; Yeole R; Thorve D; Patel M J Appl Toxicol; 2022 Aug; 42(8):1354-1370. PubMed ID: 35146781 [TBL] [Abstract][Full Text] [Related]
9. Intrapulmonary Pharmacokinetics of Levonadifloxacin following Oral Administration of Alalevonadifloxacin to Healthy Adult Subjects. Rodvold KA; Gotfried MH; Chugh R; Gupta M; Yeole R; Patel A; Bhatia A Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263070 [TBL] [Abstract][Full Text] [Related]
10. Levonadifloxacin arginine salt to treat acute bacterial skin and skin structure infection due to S. aureus including MRSA. Saxena D; Kaul G; Dasgupta A; Chopra S Drugs Today (Barc); 2020 Sep; 56(9):583-598. PubMed ID: 33025952 [TBL] [Abstract][Full Text] [Related]
11. In vitro activity of a novel antibacterial agent, levonadifloxacin, against clinical isolates collected in a prospective, multicentre surveillance study in India during 2016-18. Appalaraju B; Baveja S; Baliga S; Shenoy S; Bhardwaj R; Kongre V; Dattatraya GS; Dhole T; Verma B; Mukherjee DN; Gupta S; Shanmugam P; Iravane J; Mishra SR; Barman P; Chopra S; Hariharan M; Surpam R; Pratap R; Joshi P; Khande H; Mane A; Jain R; Bhagwat S J Antimicrob Chemother; 2020 Mar; 75(3):600-608. PubMed ID: 31840170 [TBL] [Abstract][Full Text] [Related]
12. India-discovered levonadifloxacin & alalevonadifloxacin: A review on susceptibility testing methods, CLSI quality control and breakpoints along with a brief account of their emerging therapeutic profile as a novel standard-of-care. Veeraraghavan B; Bakthavatchalam YD; Manesh A; Lal B; Swaminathan S; Ansari A; Subbareddy K; Rangappa P; Choudhuri AH; Nagvekar V; Mehta Y; Appalaraju B; Baveja S; Baliga S; Shenoy S; Bhardwaj R; Kongre V; Dattatraya GS; Verma B; Mukherjee DN; Gupta S; Shanmugam P; Iravane J; Mishra SR; Barman P; Chopra S; Hariharan M; Surpam R; Pratap R; Turbadkar D; Taklikar S; Indian J Med Microbiol; 2023; 41():71-80. PubMed ID: 36509611 [TBL] [Abstract][Full Text] [Related]